Brief: Arch Biopartners Receives Ethics Committee Approval In Turkey To Dose Additional Patients In The Phase II Trial For LSALT Peptide
02/02/2021 12:58
Feb 2 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES ETHICS COMMITTEE APPROVAL IN
TURKEY TO
DOSE ADDITIONAL PATIENTS IN THE PHASE II TRIAL FOR LSALT PEPTIDE
Source text for Eikon: ID:nGNX8wB9ks
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide